Organovo Holdings, Inc. To Present at Jefferies 2015 Healthcare Conference

Corporate Headquarters

11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121
Tel: (858) 224-1000

Find Us On

Organovo Holdings, Inc. To Present at Jefferies 2015 Healthcare Conference

SAN DIEGO, May 26, 2015 /PRNewswire/ — Organovo Holdings, Inc. (NYSE MKT: ONVO; “Organovo”), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, announced today that the company will present at an upcoming investor event, the Jefferies 2015 Healthcare Conference, to be held in New York, June 1 – 4, 2015.  Keith Murphy , Chairman and Chief Executive Officer, will deliver a company presentation and discuss recent key advances and partnerships.
Details of the presentations are as follows:

Speaker: Keith Murphy, Chairman and Chief Executive Officer


Monday, June 1, 2015, 10 a.m. ET

Organovo’s 3D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. The company recently announced advances in bioprinting of kidney tissue; collaborations with L’Oreal to produce skin tissue for research and in vitro toxicity testing; and with Merck to develop multiple new 3D tissues, as well as to bioprint liver tissues for studies of drug toxicity; and with Yale School of Medicine to develop 3-D organ tissues for surgical transplantation research. Organovo was named one of The World’s Top 10 Most Innovative Companies of 2015 in Health Care by Fast Company.
An overview of Organovo’s 3D bioprinting technology is available via video presentation at the Company’s website:
The Jefferies 2015 Healthcare Conference will feature an extensive range of public and private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare IT and medical technology sectors. This global gathering of leading executives, institutional investors, private equity investors and VCs will address near- and long-term investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally.
For more information about Organovo’s participation in industry events, please visit:
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo’s 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The company recently launched its initial product of the planned exVive3DTM portfolio offering, a 3D Human Liver Tissue for use in Toxicology and other preclinical drug testing. Additional products are in development, with anticipated release for an exVive3DTM Human Kidney Tissue in the latter half of calendar year 2016. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous other media outlets. Organovo is changing the shape of medical research and practice. Learn more at
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the market acceptance of the Company’s products; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Quarterly Report on Form 10-Q filed with the SEC on February 6, 2015.  You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
Sign up for email updates and connect with us on Twitter (@Organovo).

To view the original version on PR Newswire, visit:

SOURCE Organovo Holdings, Inc.

Organovo Holdings, Inc., Barry Michaels, Chief Financial Officer, 1-858-224-1000 ex. 3,, or Gerry Amato, Amato & Partners, LLC,